drugset / Trial / NCT07416552
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.
Timeline
- Start
- 2026-07-31
- Primary completion
- 2034-02-12
- Completion
- 2034-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 203Pb-DOTAM | Diagnostic / imaging agent | — | — |
| Subject | 212Pb-DOTAM | Other / unclassified | — | — |
| Subject | SPLIT Abs | Protein / enzyme biologic | — | Intravenous |